get a key
steadybase-$ company TIL
account_id none on file
legal_name Instil Bio, Inc.
ticker TIL
cik 1789769
domain instilbio.com
entry_point_account_id none on file
name Instil Bio Inc.
exchange Nasdaq
sector Health Care
calls 0 filings 6 executives 1 family 0
why_nownone on file
callsnone on file
filings
General and administrative expenses also include professional fees paid for accounting, auditing, legal, tax and consulting services, insurance costs, recruiting costs, travel expenses, facility and other related costs, depreciation, and other general and administrative costs.

filing / Aug 13, 2026 / receipt

In January 2023, the Board of Directors approved a restructuring plan and the Company announced the consolidation of the ITIL-306 Phase 1 clinical trial, which included contract terminations.

filing / Aug 13, 2026 / receipt

In January 2024, the Board of Directors approved a comprehensive restructuring plan, which included the closure of the Company’s UK manufacturing facility and clinical trial operations.

filing / Aug 13, 2026 / receipt

General and administrative expenses also include professional fees paid for accounting, auditing, legal, tax and consulting services, insurance costs, recruiting costs, travel expenses, facility and other related costs, depreciation, and other general and administrative costs.

filing / May 15, 2026 / receipt

In January 2023, the Board of Directors approved a restructuring plan and we announced the consolidation of the ITIL-306 Phase 1 clinical trial, which included contract terminations.

filing / May 15, 2026 / receipt

In January 2023, the Board of Directors approved a restructuring plan and the Company announced the consolidation of the ITIL-306 Phase 1 clinical trial, which included contract terminations.

filing / May 15, 2026 / receipt

executives
Timothy L. Moore Chief Operating Officer - receipt
familynone on file
upcoming
2026-11-12 earnings call scheduled ir
changes
2022-09-06 Chief Operating Officer, appointed sec_8k
mcp_package_hint
steadybase-$